Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Debt Issuances (2019 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Long-Term Debt Issuances over the past 7 years, most recently at $31.8 million for Q3 2024.

  • Quarterly results put Long-Term Debt Issuances at $31.8 million for Q3 2024, changed N/A from a year ago — trailing twelve months through Aug 2024 was $178.0 million (changed N/A YoY), and the annual figure for FY2025 was $128.6 million, down 14.05%.
  • Long-Term Debt Issuances for Q3 2024 was $31.8 million at Lifecore Biomedical, Inc. \De\, down from $149.6 million in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for LFCR hit a ceiling of $150.0 million in Q1 2021 and a floor of -$3.4 million in Q2 2023.
  • Median Long-Term Debt Issuances over the past 3 years was $31.8 million (2024), compared with a mean of $69.6 million.
  • Peak annual rise in Long-Term Debt Issuances hit 4542.71% in 2024, while the deepest fall reached 4542.71% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Long-Term Debt Issuances stood at $20.0 million in 2021, then crashed by 116.84% to -$3.4 million in 2023, then surged by 1045.17% to $31.8 million in 2024.
  • The last three reported values for Long-Term Debt Issuances were $31.8 million (Q3 2024), $149.6 million (Q2 2024), and -$3.4 million (Q2 2023) per Business Quant data.